Detalles de la búsqueda
1.
Cancer drugs with high repositioning potential for Alzheimer's disease.
Expert Opin Emerg Drugs
; 28(4): 311-332, 2023 12.
Artículo
Inglés
| MEDLINE | ID: mdl-38100555
2.
Immune profiling reveals the diverse nature of the immune response in NSCLC and reveals signaling pathways that may influence the anti-tumor immune response.
Exp Mol Pathol
; 109: 1-15, 2019 08.
Artículo
Inglés
| MEDLINE | ID: mdl-30953647
3.
Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.
Toxicol Appl Pharmacol
; 285(1): 51-60, 2015 May 15.
Artículo
Inglés
| MEDLINE | ID: mdl-25841593
4.
A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration.
Nat Cell Biol
; 9(8): 961-9, 2007 Aug.
Artículo
Inglés
| MEDLINE | ID: mdl-17643115
5.
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
Breast Cancer Res
; 15(5): R85, 2013.
Artículo
Inglés
| MEDLINE | ID: mdl-24044505
6.
Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes.
Toxicol Appl Pharmacol
; 272(1): 245-55, 2013 Oct 01.
Artículo
Inglés
| MEDLINE | ID: mdl-23707608
7.
Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.
Breast Cancer Res Treat
; 124(1): 1-11, 2010 Nov.
Artículo
Inglés
| MEDLINE | ID: mdl-20803067
8.
Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.
Cancer Res
; 67(3): 1170-5, 2007 Feb 01.
Artículo
Inglés
| MEDLINE | ID: mdl-17283152
9.
Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
Cancer Res
; 66(3): 1640-7, 2006 Feb 01.
Artículo
Inglés
| MEDLINE | ID: mdl-16452223
10.
Cyclin E and survival in patients with breast cancer.
N Engl J Med
; 347(20): 1566-75, 2002 Nov 14.
Artículo
Inglés
| MEDLINE | ID: mdl-12432043
11.
Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.
Clin Cancer Res
; 23(12): 2991-3002, 2017 Jun 15.
Artículo
Inglés
| MEDLINE | ID: mdl-27881578
12.
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
J Clin Oncol
; 23(11): 2502-12, 2005 Apr 10.
Artículo
Inglés
| MEDLINE | ID: mdl-15684311
13.
Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors.
Mol Cancer Ther
; 15(7): 1746-56, 2016 07.
Artículo
Inglés
| MEDLINE | ID: mdl-27196778
14.
AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival.
Oncogene
; 21(22): 3532-40, 2002 May 16.
Artículo
Inglés
| MEDLINE | ID: mdl-12032855
15.
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.
Clin Cancer Res
; 9(7): 2478-86, 2003 Jul.
Artículo
Inglés
| MEDLINE | ID: mdl-12855621
16.
A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity.
Toxicol Sci
; 143(1): 147-55, 2015 Jan.
Artículo
Inglés
| MEDLINE | ID: mdl-25304212
17.
Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor.
PLoS One
; 10(11): e0142845, 2015.
Artículo
Inglés
| MEDLINE | ID: mdl-26571496
18.
KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells.
Mol Cancer Ther
; 13(6): 1611-24, 2014 Jun.
Artículo
Inglés
| MEDLINE | ID: mdl-24688052
19.
Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing.
Clin Cancer Res
; 17(18): 6061-70, 2011 Sep 15.
Artículo
Inglés
| MEDLINE | ID: mdl-21810917
20.
Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.
Mol Cancer Ther
; 10(8): 1367-74, 2011 Aug.
Artículo
Inglés
| MEDLINE | ID: mdl-21673090